Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II randomized double-blind placebo-controlled multiple-dose intravenous GR1603 study in moderate to severe systemic lupus erythematosus
CTR20213169Phase 2Completed
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GR1603 in systemic lupus erythematosus (SLE), sponsored by Zhixiang Jintai. Started Mar 2022; status: completed.
02
Drugs
GR1603
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20213169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213169.